Jasper Therapeutics (JSPR) Operating Expenses (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Operating Expenses of $15.8 million for Q4 2025, down 37.36% year-over-year from $25.3 million in Q4 2024, and down 17.36% quarter-over-quarter from $19.2 million in Q3 2025.
Jasper Therapeutics (JSPR) Operating Expenses (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Operating Expenses history runs 6 years deep, the most recent figure standing at $15.8 million for Q4 2025.
- In Q4 2025, Operating Expenses fell 37.36% year-over-year to $15.8 million; the TTM figure through Dec 2025 stood at $83.9 million (up 10.03% YoY), while the FY2025 annual figure was $83.9 million, up 10.03% from the prior year.
- Operating Expenses for Q4 2025 stood at $15.8 million, down from $19.2 million in the prior quarter.
- The five-year high for Operating Expenses was $27.1 million in Q2 2025, with the low at $6.3 million in Q1 2021.
- The 5-year median for Operating Expenses is $15.5 million (2024), against an average of $15.9 million.
- The sharpest annual moves came in 2021 and 2025: Operating Expenses jumped 2634.99% in 2021, then plunged 37.36% in 2025.
- Jasper Therapeutics' Operating Expenses stood at $12.1 million in 2021, then grew by 13.78% to $13.7 million in 2022, then advanced by 28.94% to $17.7 million in 2023, then jumped by 42.65% to $25.3 million in 2024, then slumped by 37.36% to $15.8 million in 2025.
- Business Quant data shows JSPR's Operating Expenses at $15.8 million in Q4 2025, $19.2 million in Q3 2025, and $27.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Jasper Therapeutics | 20.06 Mn | 20.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.84 Mn |
| Sep 30, 2025 | 19.17 Mn |
| Jun 30, 2025 | 27.08 Mn |
| Mar 31, 2025 | 21.80 Mn |
| Dec 31, 2024 | 25.29 Mn |
| Sep 30, 2024 | 19.89 Mn |
| Jun 30, 2024 | 15.99 Mn |
| Mar 31, 2024 | 15.07 Mn |
| Dec 31, 2023 | 17.73 Mn |
| Sep 30, 2023 | 19.36 Mn |
| Jun 30, 2023 | 17.83 Mn |
| Mar 31, 2023 | 13.95 Mn |
| Dec 31, 2022 | 13.75 Mn |
| Sep 30, 2022 | 12.71 Mn |
| Jun 30, 2022 | 11.96 Mn |
| Mar 31, 2022 | 12.78 Mn |
| Dec 31, 2021 | 12.08 Mn |
| Sep 30, 2021 | 10.08 Mn |
| Jun 30, 2021 | 8.42 Mn |
| Mar 31, 2021 | 6.25 Mn |